SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

25 Jul 2018 07:00

RNS Number : 6057V
James Halstead PLC
25 July 2018
 

25 July 2018

 

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2018.

 

We are pleased to report that sales for the year were ahead of the comparative year. This represents a creditable performance in still difficult trading conditions. It is particularly pleasing to report that our UK turnover is 3% ahead of the prior year in a market that seems to be quite robust despite the well reported spending cuts and high street retailer issues.

 

In the Chairman's interim statement, announced on 29 March 2018, it was noted that adverse price pressure on raw materials was holding back the benefits of export currency gains. This continued in the second half year but was ameliorated by increased sales. The Chairman, in that statement, noted that a German competitor had entered administration and at that time we decided to undertake our largest ever re-vamp of our homogenous flooring ranges with the launch of "Palettone."

 

Palettone is a premium homogenous sheet vinyl collection, launched in May 2018. It is the largest new product development by any manufacturer in this core product area in many years. It offers a collection of 50 colours optimised for our global market and is presented in a unique, innovative sample package with full customer support from specification to installation. The feedback we have received on the collection since launch has been exceptional.

 

The costs of development trials, sampling, marketing material and related costs have been around £2 million and the product has just been launched into the global market place. The timescale that our production and marketing staff worked to was ambitious and we are delighted with the successful launch.

 

In line with best practice, we shall expense these costs rather than amortise or construct an adjustment to "underlying" earnings.

 

Consequently we are pleased to anticipate, once again, reporting record turnover and expect profits for the year to 30 June 2018 will be in line with last year.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

 

Mark Halstead, Chief Executive

 

Gordon Oliver, Finance Director

Telephone: 0161 767 2500

 

 

Nick Lyon - Hudson Sandler

Telephone: 020 7796 4133

 

 

Ben Thorne

Dominic Morley - Panmure Gordon

(Nominated advisor and broker)

 

Telephone: 020 7886 2500

 

Chris Hardie - Arden Partners

Telephone: 020 7614 5900

(Broker)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBZLFLVDFEBBX
Date   Source Headline
9th Apr 20265:32 pmRNSGrant of Options
8th Apr 20265:19 pmRNSHolding(s) in Company
31st Mar 20267:00 amRNSInterim Results
23rd Feb 20264:48 pmRNSPDMR Acquisition of Shares
30th Jan 20263:32 pmRNSShare Buyback - Replacement
30th Jan 20262:44 pmRNSShare Buyback
29th Jan 20267:00 amRNSTrading Update
8th Jan 20268:20 amRNSBlock Listing Six Monthly Return
5th Dec 20251:00 pmRNSResult of AGM
5th Dec 20257:00 amRNSChairman’s Statement to the Annual General Meeting
14th Nov 202512:12 pmRNSDirector/PDMR Shareholding
14th Nov 202512:11 pmRNSDirector/PDMR Shareholding
17th Oct 20257:00 amRNSPosting of Annual Report and Notice of AGM
1st Oct 20257:00 amRNSPreliminary Results
8th Sep 20257:00 amRNSNotice of Preliminary Results
29th Aug 20253:55 pmRNSBLOCK LISTING SIX MONTHLY RETURN
29th Jul 20257:00 amRNSTrading Update
9th Apr 20255:32 pmRNSHolding(s) in Company
7th Apr 202512:25 pmRNSDirector/PDMR Shareholding
27th Mar 20257:00 amRNSInterim Results
6th Mar 202510:41 amRNSNotice of Interim Results - Replacement
6th Mar 20259:00 amRNSNotice of Inteirm Results
6th Mar 20257:00 amRNSNotice of Interim Results
31st Jan 20257:00 amRNSTrading Update and Notice of Results
27th Jan 20255:09 pmRNSDirector/PDMR Shareholding
6th Jan 20253:15 pmRNSBlock Listing Six Monthly Return
6th Dec 20242:09 pmRNSResults of AGM
6th Dec 20247:00 amRNSAGM Statement
18th Oct 20249:20 amRNSPosting of Annual R&A and Notice of AGM
1st Oct 20247:00 amRNSBoard Changes
1st Oct 20247:00 amRNSPreliminary Results
7th Aug 20248:05 amRNSBlock Listing Six Monthly Return
31st Jul 20247:00 amRNSTrading Update
15th Jul 20247:00 amRNSChange of Broker
8th Apr 20244:54 pmRNSPDMR Exercise of Share Options
3rd Apr 20242:00 pmRNSPDMR Acquisition of Shares
28th Mar 202412:00 pmRNSPDMR Grant of Share Options
27th Mar 20247:00 amRNSInterim Results
5th Mar 202412:30 pmRNSAppointment of Senior Independent Director
31st Jan 20247:00 amRNSTrading Update
4th Jan 20244:34 pmRNSBoard Changes
1st Dec 20232:25 pmRNSResults of Annual General Meeting
1st Dec 20237:00 amRNSAGM Statement
17th Nov 202311:13 amRNSPDMR Grant of Share Options
10th Nov 20234:45 pmRNSBlock Listing Six Monthly Return
10th Nov 20234:43 pmRNSBlock Listing Six Monthly Return
13th Oct 202312:00 pmRNSPosting of Annual R&A and Notice of AGM
2nd Oct 20237:00 amRNSPreliminary Results
1st Aug 20237:00 amRNSTrading Update
31st Mar 20231:57 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.